Abstract
We have created a double mutant of the herpes simplex virus (HSV) type 1 (termed G207) with favourable properties for treating human malignant brain tumours: replication–competence in glioblastoma cells (and other dividing cells), attenuated neurovirulence, temperature sensitivity, ganciclovir hypersensitivity, and the presence of an easily detectable histochemical marker. G207 has deletions at both γ34.5 (RL1) loci and a lacZ gene insertion inactivating the ICP6 gene (UL39). G207 kills human glioma cells in monolayer cultures. In nude mice harbouring subcutaneous or intracerebral U–87MG gliomas, intraneoplastic inoculation with G207 causes decreased tumour growth and/or prolonged survival. G207 is avirulent upon intracerebral inoculation of mice and HSV–sensitive non–human primates. These results suggest that G207 should be considered for clinical evaluation in the treatment of glioblastomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mahaley, M.S. Jr, Mettlin, C., Natarajan, N., Laws, E.R. Jr & Peace, B.B. National survey of patterns of care for brain-tumor patients. J. Neurosurg. 71, 826–836 (1989).
Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. & Coen, D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854–856 (1991).
Markert, J.M., Malick, A., Coen, D.M. & Martuza, R.L. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 35, 597–603 (1993).
Mineta, T., Rabkin, S.D. & Martuza, R.L. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 54, 3963–3966 (1994).
Kaplitt, M.G. et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J. Neuro-Oncol. 19, 137–147 (1994).
Jia, W.W., McDermott, M., Goldie, J., Cyander, M., Tan, J. & Tufaro, F. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J. natn. Cancer Inst. 86, 1209–1215 (1994).
Boviatsis, E.J. et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1, 323–331 (1994).
Coen, D.M. et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeninal ganglia but do not reactivate. Proc. natn. Acad. Sci. U.S.A. 86, 4736–4740 (1989).
Goldstein, D.J. & Weller, S.K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensible for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196–205 (1988).
Chou, J., Kern, E.R., Whitley, R.J. & Roizman, B. Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250, 1262–1266 (1990).
Preston, V.G., Palfreyman, J.W. & Duita, B.M. Identification of a herpes simplex virus type 1 polypeptide which is a component of the virus-induced ribonucleotide reductase. J. gen. Virol. 65, 1457–1466 (1984).
Jacobson, J.G. et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173, 276–283 (1989).
Chou, J. & Roizman, B. The terminal a sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component. J. Virol. 57, 629–637 (1986).
Dolan, A., McKie, E., MacLean, A.R. & McGeoch, D.J. Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17. J. gen. Virol 73, 971–973 (1992).
Whitley, R.J., Kern, E.R., Chatterjee, S., Chou, J. & Roizman, B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 34.5 deletion mutants in rodent models. J. clin. Invest. 91, 2837–2843 (1993).
MacLean, A.R., Ul-Fareed, M., Robertson, L., Harland, J. & Brown, S.M. Herpes simplex virus type 1 variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequence. J. gen. Virol. 72, 631–639 (1991).
Bolovan, C.A., Sawtell, N.M. & Thompson, R.L. ICP34.5 mutants of herpes simplex virus type 1 strain 17 syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J. Virol. 68, 48–55 (1994).
Ausubel, F.M. et al. Current Protocols in Molecular Biology (Wiley-Interscience, New York, 1991).
Southern, E.M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. molec. Biol. 98, 503–517 (1975).
Knipe, D.M., Batterson, W., Nosal, C., Roizman, B. & Buchan, A. Molecular genetics of herpes simplex virus. VI. Characterization of a temperature-sensitive mutant defective in the expression of all early viral gene products. J. Virol. 38, 539–547 (1981).
Goldstein, D.J. & Weller, S.K. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 166, 41–51 (1988).
Coen, D.M., Goldstein, D.J. & Weller, S.K. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob. Agents Chemother. 33, 1395–1399 (1989).
Yamada, Y. et al. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type1 in mice. J. infect. Dis. 164, 1091–1097 (1991).
Cameron, J.M. et al. Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J. gen. Virol. 69, 2607–2612 (1988).
Hershkovitz, P. Two new species of night monkeys, genus Aotus (Cebidae, Platyrhini): A preliminary report on Aotus taxonomy. Am. J. Primatol. 4, 209–243 (1983).
Aikawa, M. et al. An atlas of renal disease in Aotus monkeys with experimental plasmodial infection (American Institute of Biological Sciences, Washington, DC, 1988).
Hunt, R.D. Herpesvirus simplex infection. in Nonhuman Primates, Vol. I (eds Jones, T.C., Mohr, U. & Hunt, R.D.) 82–86 (Springer, Berlin, 1993).
Katzin, D.S., Connor, J.D., Wilson, L.A. & Sexton, R.S. Experimental herpes simplex infection in the owl monkey. Proc. Soc. exp. Biol. Med. 125, 391–398 (1967).
Melendez, L.V., Espana, C., Hunt, R.D., Daniel, M.D. & Garcia, F.G. Natural herpes simplex infection in the owl monkey (Aotus trivirgatus). Lab. Anim. Care 19, 38–45 (1969).
Meignier, B., Martin, B., Whitley, R.J. & Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. infect. Dis. 162, 313–321 (1990).
Baringer, J.R. & Pisani, P. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann. Neurol. 36, 823–829 (1994).
Asou, H., Hirano, S. & Kohsaka, S. Changes in ganglioside composition and morphological features during the development of cultured astrocytes from rat brain. Neurosci. Res. 6, 369–375 (1989).
McCarthy, K.D. & de Vellis, J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 85, 890–902 (1980).
Messer, A. The maintenance and identification of mouse cerebellar granule cells in monolayer culture. Brain Res. 130, 12–23 (1977).
Kaplitt, M.G. et al. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Molec. cell. Neurosci. 2, 320–330 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mineta, T., Rabkin, S., Yazaki, T. et al. Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas. Nat Med 1, 938–943 (1995). https://doi.org/10.1038/nm0995-938
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0995-938
This article is cited by
-
Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12
Communications Medicine (2023)
-
Current advances in microbial-based cancer therapies
Medical Oncology (2023)
-
A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma
Nature Communications (2022)
-
Effects of oncolytic viruses and viral vectors on immunity in glioblastoma
Gene Therapy (2022)
-
Implications of immune cells in oncolytic herpes simplex virotherapy for glioma
Brain Tumor Pathology (2022)